Somatostatin Analogs Market Size, Share, Trends, Growth and Forecast 2025

Somatostatin Analogs Market

Somatostatin Analogs Market: by Indication (acromegaly, NETs, and others), Type (octreotide, lanreotide, and pasireotide)– Global Industry Perspective Comprehensive Analysis and Forecast, 2019-2025

Category: Healthcare Report Format : PDF Pages: 130 Report Code: ZMR-4949 Published Date: Oct-2019 Status : Published
Market Size in 2018 Market Forecast in 2026 CAGR (in %) Base Year
USD 5.51 Billion USD 8.38 Billion 6.25% 2018

Somatostatin Analogs Market Size: Overview

 According to the report, global demand for Somatostatin Analogs market was valued at approximately USD 5.51 Billion in 2018 and is expected to generate revenue of around USD 8.38 Billion by end of 2025, growing at a CAGR of around 6.25% between 2019 and 2025. 

The report covers forecasts and analysis for the Somatostatin Analogs market on a global and regional level. The study provides historic data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints for the Somatostatin Analogs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Somatostatin Analogs market on a global level. In order to give the users of this report a comprehensive view of the Somatostatin Analogs market, we have included a competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein indication, type, and regional segments are benchmarked based on their market size, growth rate, and general attractiveness.

Global Somatostatin Analogs Market SizeRequest Free Sample

Somatostatin analogs are medications that stop too many hormones in your body. Many neuroendocrine tumors (NETs) make large quantities of hormones that cause a group of symptoms called carcinoid syndrome. In people with carcinoid syndrome, somatostatin analogs are a possible treatment. There are a number of things Somatostatin does. A variety of hormones such as insulin and gut hormones are slowed down or halted. It also regulates the stomach and intestine emptying. A somatostatin analog is a man-made somatostatin (synthetic) form. This slows hormone production, especially growth hormone and serotonin. It helps control carcinoid syndrome symptoms such as diarrhea and skin flushing. It can shorten the NET as well.

Global Somatostatin Analogs Market Size: Segmentation

The study provides a decisive view of the Somatostatin Analogs market by segmenting the market based on indication, type, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. Based on type, the market is segmented into octreotide, lanreotide, and pasireotide. Due to its various therapeutic applications such as acromegaly, carcinoid tumors, and vasoactive intestinal peptide tumors, octreotide dominated the overall category segment in 2018.

Based on indication, the market is segmented into acromegaly, NETs, and others. In 2018, blood transfusion therapy held the largest market share. Acromegaly is projected to be the largest segment in 2018 and the fastest growing segment over the forecast period. Increasing acromegaly awareness coupled with the availability of effective treatment options is considered to be the major factor driving growth in the segment. For example, in November 2018, Acromegaly Awareness Day was held in Canada, providing various acromegaly information along with the treatment options available and their benefits.

Global Somatostatin Analogs Market Size: Regional Analysis

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa with its further bifurcation into major countries such as the US, Canada, Germany, UK, France, China, Japan, India, GCC countries, Brazil. North America dominated the market. The initial factors responsible for local growth are expected to be the high prevalence of acromegaly and NETs. It is also anticipated that the presence of key players in the region such as Pfizer Inc. and Novartis AG, as well as increasing awareness among individuals, would drive market growth.

Some of the factors driving the growth of the demand for somatostatin analogs are growing R&D initiatives and the release of novel drug therapies. For starters, Novartis AG introduced Signifor (Pasireotide) in 2012 to treat Cushing's syndrome and acromegaly in 2014. Another key contributing factor to overall market growth is the presence of favorable government insurance policies & schemes for rare disease patients. For example, multiple government healthcare agencies in the U.S. and Europe, such as the National Institutes of Health (NIH) and the National Center of Advancing Translational Sciences (NCATS), provide affordable rare disease medicines.

Somatostatin Analogs Market Size: Report Scope

Report Attributes Report Details
Report Name Somatostatin Analogs Market Size Report
Market Size in 2018 USD 5.51 Billion/td>
Market Forecast in 2026 USD 8.38 Billion
Growth Rate CAGR of 6.25%
Number of Pages 188
Forecast Units Value (USD Billion), and Volume (Units)
Key Companies Covered Camurus AB, Chiasma Inc., CRINETICS PHARMACEUTICALS, Dauntless Pharmaceuticals, Ipsen Pharma, Midatech Pharma PLC, Novartis AG, Peptron, Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd, and Teva Pharmaceuticals Inc amongst others.
Segments Covered By Type, By Indication By End-Use And By Region.
Base Year 2018
Historical Year 2015 to 2018
Forecast Year 2018 - 2026
Customization Scope Avail customized purchase options to meet your exact research needs. Request For Customization

Somatostatin Analogs Market Size: Competitive Players

Key players within the global Somatostatin Analogs market include:

  • Camurus AB
  • Chiasma Inc.
  • CRINETICS PHARMACEUTICALS
  • Dauntless Pharmaceuticals
  • Ipsen Pharma
  • Midatech Pharma PLC
  • Novartis AG
  • Peptron
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceuticals Inc amongst others.

The report segments the global Somatostatin Analogs market as follows:

Global Somatostatin Analogs Market: Indication Segment Analysis

  • Acromegaly
  • Neuroendocrine Tumors (NETs)
  • Others

Global Somatostatin Analogs Market: Type Segment Analysis

  • Octreotide
  • Lanreotide
  • Pasireotide

Global Somatostatin Analogs Market: Regional Segment Analysis

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • The Middle East and Africa

Table Of Content

Methodology

FrequentlyAsked Questions

 According to the report, global demand for Somatostatin Analogs market was valued at approximately USD 5.51 Billion in 2018 and is expected to generate revenue of around USD 8.38 Billion by end of 2025

Camurus AB, Chiasma Inc., CRINETICS PHARMACEUTICALS, Dauntless Pharmaceuticals, Ipsen Pharma, Midatech Pharma PLC, Novartis AG, Peptron, Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd, and Teva Pharmaceuticals Inc amongst others.

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed